DENOSUMAB-RELATED OSTEONECROSIS OF THE JAW IN A METASTATIC PROSTATE CANCER PATIENT: CASE REPORT

DENOSUMAB-RELATED OSTEONECROSIS OF THE JAW IN A METASTATIC PROSTATE CANCER PATIENT: CASE REPORT

This is an automatically generated default intro template – please do not edit.

General information
Title:	DENOSUMAB-RELATED OSTEONECROSIS OF THE JAW IN A METASTATIC PROSTATE CANCER PATIENT: CASE REPORT
Meta keywords:
Meta description:
Images information
Images path absolute:	/home/jmedarr/public_html/images/stories/com_form2content/p2/f373
Images path relative:	com_form2content/p2/f373
Thumbs path absolute:
Thumbs path relative:
Fields information
Article_Title:	DENOSUMAB-RELATED OSTEONECROSIS OF THE JAW IN A METASTATIC PROSTATE CANCER PATIENT: CASE REPORT
Authors:	Octavian Dincă1,Mihai Bogdan Bucur2, Nicoleta Măru3 Ioan Liviu Tuturici4, Roxana Radu, Cristian Vladan5, Alexandru Bucur6
Affiliation:	1 Associate Professor, Faculty of Dental Medicine, “Carol Davila” University of Medicine and Pharmacy, Bucharest 2 Teaching Assistant, Faculty of Nursing and Midwifery,“ Carol Davila” University of Medicine and Pharmacy, Bucharest 3 Lecturer, M.D. Ph.D., Faculty of Dental Medicine, “Carol Davila” University of of Medicine and Pharmacy, Bucharest 4 Teaching Assistant, Faculty of Dental Medicine, University of West „Vasile Goldis” Arad 5 Teaching Assistant, Faculty of Dental Medicine, “ Carol Davila” University of Medicine and Pharmacy, Bucharest 6 Professor, Faculty of Dental Medicine, “ Carol Davila” University of Medicine and Pharmacy, Bucharest
Abstract:	Osteonecrosis of the jaw (ONJ) is a clinical condition characterized by the presence of exposed necrotic bone in the maxillofacial region. Its pathogenesis is still undetermined, but may be associated with risk factors such as bisphosphonates. The aim of this paper is to report a case of ONJ in a patient with metastatic prostate cancer and a history of Denosumab use.
Keywords:	osteonecrosis of the jaw (ONJ), human RANKL monoclonal antibody, bisphosphonates, dental extraction, metastases.
References:	Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonates-induced exposed bone of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63:1567–75 AAOMS. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonates-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65:369–76 Aghaloo TL,Felsenfeld AL,Tetradis S. Osteonecrosis of the Jaw in a Patient on Denosumab.J Oral Maxillofac Surg. 2010 May; 68(5): 959–63 Amgen Incorporated. XGEVA (denosumab) injection, for subcutaneous use: US prescribing information [online] Thousand Oaks, CA: Amgen Inc; 2010. http://pi.amgen.com/united_states/xgeva/xgeva_pi.pdf. Amgen Incorporated. Prolia™ (Denosumab) injection, for subcutaneous use: US prescribing information [online] Thousand Oaks, CA: Amgen Inc; 2010. [Accessed May 1, 2012]. http://pi.amgen.com/united_states/prolia/prolia_pi.pdf. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaws and bisphosphonates. N Engl J Med. 2005;353(1):99–102 Epstein MS, Ephros HD, Epstein JB.Review of current literature and implications of RANKL inhibitors for oral health care providers. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012. PMID: 22901640 DOI: 10.1016/j.oooo.2012.01.046 Fizazi K, Carducci MA, Smith MR, et al: A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol, 2010, 28:343s (suppl; abstr LBA4507) Fizazi K et al.Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011 Mar 5;377(9768):813-22. doi: 10.1016/S0140-6736(10)62344-6 Greenberg MS. Intravenous bisphosphonates and osteonecrosis. [Editorial] Oral Surg Oral Med Oral Pathol Oral Radiol Endond. 2004;93:259–60 Kostenuik PJ, Nguyen HQ, McCabe J, et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res. 2009;24(2):182–95. Patschan D, Loddenkemper K, Buttgereit F. Molecular mechanisms of glucocorticoid-induced osteoporosis Bone 2001; 29: 498-05. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62:527–34 Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Sur Oral Pathol Oral Med. 2006;102:433–41 Sarin J, DeRossi S S, Akintoye S O. Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis. Oral Dis 2008; 14: 277-85 Shore N, Goessl C. Effects of Denosumab versus Zoledronic Acid in Patients with Castration-Resistant Prostate Cancer and Bone Metastases.Oncology & Hematology Review (US), 2012;8(2):94-9 Smith MR.Osteoclast-targeted therapy for prostate cancer.Curr Treat Options Oncol. 2004 Oct;5(5):367-75 Smith MR, Egerdie B, Hernádez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361:745–55 Tannock IF, de Wit R, Berry WR, et al. for TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12 Vescovi P, Nammour S. Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) therapy. A critical review. Minerva Stomatol. 2010 Apr;59(4):181-203, 204-13 Woo S-B, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144:753–61
Read_full_article:	pdf/vol18/iss1/8 JMA 2015 – Liviu tuturici – BUCHAREST CASE REPORTz.pdf
Correspondence:

	Read full article
Article Title:	DENOSUMAB-RELATED OSTEONECROSIS OF THE JAW IN A METASTATIC PROSTATE CANCER PATIENT: CASE REPORT
Authors:	Octavian Dincă1,Mihai Bogdan Bucur2, Nicoleta Măru3 Ioan Liviu Tuturici4, Roxana Radu, Cristian Vladan5, Alexandru Bucur6
Affiliation:	1 Associate Professor, Faculty of Dental Medicine, “Carol Davila” University of Medicine and Pharmacy, Bucharest 2 Teaching Assistant, Faculty of Nursing and Midwifery,“ Carol Davila” University of Medicine and Pharmacy, Bucharest 3 Lecturer, M.D. Ph.D., Faculty of Dental Medicine, “Carol Davila” University of of Medicine and Pharmacy, Bucharest 4 Teaching Assistant, Faculty of Dental Medicine, University of West „Vasile Goldis” Arad 5 Teaching Assistant, Faculty of Dental Medicine, “ Carol Davila” University of Medicine and Pharmacy, Bucharest 6 Professor, Faculty of Dental Medicine, “ Carol Davila” University of Medicine and Pharmacy, Bucharest
Abstract:	Osteonecrosis of the jaw (ONJ) is a clinical condition characterized by the presence of exposed necrotic bone in the maxillofacial region. Its pathogenesis is still undetermined, but may be associated with risk factors such as bisphosphonates. The aim of this paper is to report a case of ONJ in a patient with metastatic prostate cancer and a history of Denosumab use.
Keywords:	osteonecrosis of the jaw (ONJ), human RANKL monoclonal antibody, bisphosphonates, dental extraction, metastases.
References:	Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonates-induced exposed bone of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63:1567–75 AAOMS. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonates-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65:369–76 Aghaloo TL,Felsenfeld AL,Tetradis S. Osteonecrosis of the Jaw in a Patient on Denosumab.J Oral Maxillofac Surg. 2010 May; 68(5): 959–63 Amgen Incorporated. XGEVA (denosumab) injection, for subcutaneous use: US prescribing information [online] Thousand Oaks, CA: Amgen Inc; 2010. http://pi.amgen.com/united_states/xgeva/xgeva_pi.pdf. Amgen Incorporated. Prolia™ (Denosumab) injection, for subcutaneous use: US prescribing information [online] Thousand Oaks, CA: Amgen Inc; 2010. [Accessed May 1, 2012]. http://pi.amgen.com/united_states/prolia/prolia_pi.pdf. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaws and bisphosphonates. N Engl J Med. 2005;353(1):99–102 Epstein MS, Ephros HD, Epstein JB.Review of current literature and implications of RANKL inhibitors for oral health care providers. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012. PMID: 22901640 DOI: 10.1016/j.oooo.2012.01.046 Fizazi K, Carducci MA, Smith MR, et al: A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol, 2010, 28:343s (suppl; abstr LBA4507) Fizazi K et al.Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011 Mar 5;377(9768):813-22. doi: 10.1016/S0140-6736(10)62344-6 Greenberg MS. Intravenous bisphosphonates and osteonecrosis. [Editorial] Oral Surg Oral Med Oral Pathol Oral Radiol Endond. 2004;93:259–60 Kostenuik PJ, Nguyen HQ, McCabe J, et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res. 2009;24(2):182–95. Patschan D, Loddenkemper K, Buttgereit F. Molecular mechanisms of glucocorticoid-induced osteoporosis Bone 2001; 29: 498-05. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62:527–34 Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Sur Oral Pathol Oral Med. 2006;102:433–41 Sarin J, DeRossi S S, Akintoye S O. Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis. Oral Dis 2008; 14: 277-85 Shore N, Goessl C. Effects of Denosumab versus Zoledronic Acid in Patients with Castration-Resistant Prostate Cancer and Bone Metastases.Oncology & Hematology Review (US), 2012;8(2):94-9 Smith MR.Osteoclast-targeted therapy for prostate cancer.Curr Treat Options Oncol. 2004 Oct;5(5):367-75 Smith MR, Egerdie B, Hernádez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361:745–55 Tannock IF, de Wit R, Berry WR, et al. for TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12 Vescovi P, Nammour S. Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) therapy. A critical review. Minerva Stomatol. 2010 Apr;59(4):181-203, 204-13 Woo S-B, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144:753–61
*Correspondence:

About The Author

dti